{
    "Trade/Device Name(s)": [
        "MammaPrint"
    ],
    "Submitter Information": "Agendia BV",
    "510(k) Number": "K081092",
    "Predicate Device Reference 510(k) Number(s)": [
        "K080252"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI"
    ],
    "Summary Letter Date": "December 11, 2009",
    "Summary Letter Received Date": "June 23, 2009",
    "Submission Date": "June 17, 2009",
    "Regulation Number(s)": [
        "21CFR866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "70-gene profile for breast cancer prognosis"
    ],
    "Specimen Type(s)": [
        "Fresh breast cancer tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "MammaPrint microarray"
    ],
    "Method(s)/Technology(ies)": [
        "Microarray",
        "Gene expression analysis"
    ],
    "Methodologies": [
        "Gene expression profiling",
        "RNA isolation",
        "cRNA labeling",
        "Hybridization",
        "Feature extraction"
    ],
    "Submission Type(s)": [
        "Test",
        "Service"
    ],
    "Document Summary": "FDA 510(k) summary for Agendia MammaPrint gene expression profiling microarray test to assess risk of distant metastasis in breast cancer patients",
    "Indications for Use Summary": "Qualitative in vitro diagnostic gene expression profiling test service used to assess risk of distant metastasis in Stage I or II, lymph node-negative breast cancer patients with tumor size \u22645.0 cm, indicated as a prognostic marker for physician use along with other clinicopathological factors",
    "fda_folder": "Immunology"
}